Penumbra, Inc. (NYSE:PEN) EVP Sells $105,588.00 in Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $175.98, for a total transaction of $105,588.00. Following the transaction, the executive vice president now owns 61,688 shares of the company’s stock, valued at approximately $10,855,854.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Johanna Roberts also recently made the following trade(s):

• On Monday, July 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $179.20, for a total value of $107,520.00.
• On Monday, June 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $188.90, for a total value of $113,340.00.

Penumbra Stock Performance

PEN stock opened at $190.51 on Friday. The company has a 50 day moving average price of $181.38 and a 200 day moving average price of $209.00. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $302.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.25 and a quick ratio of 3.77. The stock has a market capitalization of $7.39 billion, a PE ratio of 80.38, a price-to-earnings-growth ratio of 1.90 and a beta of 0.55.

Penumbra (NYSE:PEN) last released its earnings results on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.56 by $0.08. Penumbra had a return on equity of 8.39% and a net margin of 1.26%. The company had revenue of $299.40 million during the quarter, compared to analysts’ expectations of $298.24 million. During the same period last year, the firm earned $0.43 EPS. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. Analysts forecast that Penumbra, Inc. will post 2.64 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. grew its position in shares of Penumbra by 171.8% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company’s stock worth $27,000 after buying an additional 67 shares during the period. Mather Group LLC. acquired a new stake in Penumbra during the 1st quarter worth $29,000. Signaturefd LLC raised its position in shares of Penumbra by 27.2% during the 4th quarter. Signaturefd LLC now owns 215 shares of the company’s stock valued at $54,000 after acquiring an additional 46 shares during the last quarter. WASHINGTON TRUST Co acquired a new position in shares of Penumbra in the 2nd quarter valued at $54,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Penumbra by 1,845.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 389 shares of the company’s stock valued at $70,000 after purchasing an additional 369 shares during the period. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on PEN. Robert W. Baird cut their price objective on Penumbra from $231.00 to $180.00 and set an “outperform” rating for the company in a report on Wednesday, July 31st. Morgan Stanley dropped their target price on shares of Penumbra from $235.00 to $210.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Wells Fargo & Company lowered shares of Penumbra from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $289.00 to $150.00 in a research report on Wednesday, July 31st. Truist Financial reaffirmed a “buy” rating and set a $200.00 price objective (down previously from $230.00) on shares of Penumbra in a report on Wednesday, July 31st. Finally, Royal Bank of Canada reduced their target price on Penumbra from $289.00 to $205.00 and set an “outperform” rating on the stock in a report on Wednesday, July 31st. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Penumbra has an average rating of “Moderate Buy” and an average target price of $193.60.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.